Actithera is a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs). Founded in 2021 by drug discovery innovator Dr. Andreas Goutopoulos, and seed investors M Ventures, and Arkin Bio Ventures II, Actithera applies various molecular design strategies, including covalent-targeting and an isotope-agnostic philosophy to invent RLTs with significant differentiation and larger therapeutic windows. Headquartered in Oslo, Norway, and Cambridge, Massachusetts, Actithera is committed to advancing a differentiated pipeline addressing critical unmet needs in oncology.
Company Details
- Employees
- 6
- Address
- Oslo, No
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://actithera.com/
- HQ
- Oslo
Actithera Questions
Actithera's website is https://actithera.com/
Actithera's LinkedIn profile is https://www.linkedin.com/company/actithera
Actithera has
6 employees.
View email and phone details for 6
employees at Actithera.
Actithera's industry is
Biotechnology Research
Actithera's top competitors are
Centivax,
M Ventures,
Nuclidium Ag,
Forx Therapeutics,
Varda Space Industries,
Hadean Ventures,
Metabomed Ltd.,
Renasant Bio,
4bio Capital,
Verona Pharma.
Actithera's categories are Biotechnology Research
